Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

嵌合抗原受体 癌症研究 细胞疗法 医学 T细胞 免疫疗法 表皮生长因子受体 抗原 癌症 免疫学 干细胞 生物 内科学 免疫系统 细胞生物学
作者
Hong Ma,Jeeban P. Das,Conor Prendergast,Dorine de Jong,Brian Braumuller,Jacienta Paily,Sophia Huang,Connie Liou,Anna O. Giarratana,Mahdie Hosseini,Randy Yeh,Kathleen M. Capaccione
出处
期刊:Current Issues in Molecular Biology [Caister Academic Press]
卷期号:45 (11): 9019-9038 被引量:31
标识
DOI:10.3390/cimb45110566
摘要

Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大模型应助2hi采纳,获得10
刚刚
李健应助QiQi采纳,获得10
1秒前
Nikona发布了新的文献求助10
1秒前
彧辰完成签到,获得积分10
1秒前
1秒前
1秒前
2秒前
2秒前
时尚语梦完成签到 ,获得积分10
2秒前
芋袁完成签到,获得积分10
2秒前
3秒前
小象发布了新的文献求助30
3秒前
星辰大海应助勤劳寡妇采纳,获得10
3秒前
嘿吗湾子发布了新的文献求助10
4秒前
无花果应助liun采纳,获得30
4秒前
张羽涵发布了新的文献求助10
4秒前
MrC驳回了小雨应助
4秒前
5秒前
www完成签到,获得积分10
5秒前
5秒前
我要看文献完成签到,获得积分20
5秒前
Sprites完成签到,获得积分10
6秒前
6秒前
斯文败类应助ay采纳,获得30
6秒前
英俊的铭应助嘟嘟采纳,获得10
7秒前
7秒前
hhgg完成签到,获得积分10
7秒前
7秒前
可爱的函函应助jie采纳,获得10
7秒前
8秒前
leclerc发布了新的文献求助30
8秒前
思源应助楠枫采纳,获得10
8秒前
8秒前
芋袁发布了新的文献求助10
8秒前
9秒前
MIE完成签到,获得积分10
9秒前
傲娇醉冬应助木木采纳,获得10
10秒前
丘比特应助自由念露采纳,获得10
10秒前
丢硬币的小孩完成签到,获得积分10
10秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
晶种分解过程与铝酸钠溶液混合强度关系的探讨 8888
Les Mantodea de Guyane Insecta, Polyneoptera 2000
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6422124
求助须知:如何正确求助?哪些是违规求助? 8241059
关于积分的说明 17516037
捐赠科研通 5476002
什么是DOI,文献DOI怎么找? 2892702
邀请新用户注册赠送积分活动 1869132
关于科研通互助平台的介绍 1706577